Matt Ashley, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $139,519 of the $211,598 with a category attached, or 65.9%. Teleflex LLC accounts for 94.5% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $117,322 and has fallen 59.4% since, to $47,645 in 2025. Among urology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 259 payments — averaging $816.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$200K
- Corbin Clinical Resources$5K
- Boston Scientific$3K
- Neotract Inc.$1K
- Procept Biorobotics Corporation$872
- Teleflex Incorporated$331
- plus $2K from 23 others
What the payments were for
- Consulting fees$56,28827%
- Speaking & faculty fees$139,51966%
- Travel & lodging$9,1984%
- Food & beverage$4,8232%
- Education$1,7711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 192 | $199,949 |
| Corbin Clinical Resources | 3 | $4,500 |
| Boston Scientific | 5 | $3,119 |
| Neotract Inc. | 11 | $1,326 |
| Procept Biorobotics Corporation | 7 | $872 |
| Teleflex Incorporated | 1 | $331 |
| Dendreon Pharmaceuticals LLC | 4 | $260 |
| Endo Pharmaceuticals Inc. | 2 | $205 |
| Teleflex Medical Incorporated | 1 | $172 |
| Coloplast | 2 | $142 |
| Bayer | 4 | $89 |
| BK Medical Holding Company Inc. | 1 | $73 |
| Myriad Genetic Laboratories, Inc. | 4 | $69 |
| Astellas Pharma US Inc | 1 | $65 |
| Tolmar, Inc. | 1 | $53 |
| Urogen Pharma, Inc. | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| Agiliti Surgical, Inc. | 1 | $47 |
| KARL Storz Endoscopy-america | 1 | $35 |
| Progenics Pharmaceuticals, Inc. | 1 | $30 |
| Ambu Inc. | 1 | $27 |
| AbbVie | 1 | $26 |
| EDAP Technomed Inc | 1 | $19 |
| Vertex | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Angiodynamics, Inc. | 1 | $17 |
| Profound Medical Corp. | 1 | $15 |
| Pfizer | 1 | $14 |
| Travere Therapeutics, Inc. | 5 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$106,629
- UroLift System$66,700
- UroLift 2 System$23,625
- GENERAL PELVIC ORGAN PROLAPSE$2,925
- Barrigel$1,925
- AquaBeam Robotic System$643
- Weck$331
- RUSCH$172
- PROVENGE$168
- TITAN$125
- XIAFLEX$105
- SpaceOAR System$102
How this compares
$211,598 in reported general payments places this provider in the 95th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 82 | $86,155 |
| Tamsulosin Hcl | 528 | $14,114 |
| Finasteride | 304 | $5,293 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 70 | $1,485 |
| Testosterone Cypionate | 17 | $1,135 |
| Dutasteride | 24 | $1,128 |
| Potassium Citrate ErPotassium Citrate | 12 | $1,011 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $691 |
| Oxybutynin Chloride ErOxybutynin Chloride | 19 | $643 |
| Doxazosin Mesylate | 39 | $591 |
| Terazosin Hcl | 11 | $329 |
| Cephalexin | 52 | $300 |
| Tramadol Hcl | 27 | $41 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $65 | $86,15582 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 153 urology providers in Oregon.
Other urology in Bend
- Willie UnderwoodBend$11K
- Jason FlamiatosBend$11K
- Andrew NeebBend$9K
- Hagop SarkissianBend$4K
- Michael LavelleBend$3K
- Daniel WillisBend$3K
- Bryan MehlhaffSpringfield$1M
- Lance MarrPortland$323K
- da David JiangPortland$65K
- Kim ThaiMedford$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.